Cited by 137Protein Kinase Regulation and GTPase SignalingDNA Repair MechanismsPARP inhibition in cancer therapy

PARP-1 activation in the ERK signaling pathway

COHENARMON, M·2007·Trends in Pharmacological Sciences

Abstract

PARP-1 is a highly conserved DNA-binding protein, the most abundant member of the polyADP-ribose polymerases (PARP) family, which catalyzes post-translational modification of proteins by polyADP-ribosylation. This modification affects protein-protein and protein-DNA interactions. Binding of PARP-1 to breakages in damaged DNA causes its activation and auto-polyADP-ribosylation in a process that is pivotal for DNA repair. Our recent findings outlined an alternative mechanism of PARP-1 activation via a direct interaction with phosphorylated ERK2 (externally regulated kinase), which is unrelated to DNA damage and does not involve PARP-1 binding to DNA. Furthermore, ERK2-induced PARP-1 activation dramatically amplifies ERK-signals, enhancing ERK-induced phosphorylation of the transcription factor Elk1 and enhancing core histone acetylation and expression of the Elk1 target gene, c-fos. Thus, PARP-1 activation in the ERK signaling pathway mediates epigenetic mechanisms promoting growth, proliferation and differentiation regulated by the Raf-MEK-ERK phosphorylation cascade.

Integrity signals

Registry

Crossref · 10.1016/j.tips.2007.08.005

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
COHENARMON, M.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2007-11
Volume
28
Issue
11
Pages
556-560
ISSN
0165-6147 (ISSN-L)
OpenAlex
W2013220294
Cited by
137
References
37
Citations by year
2026: 4 · 2025: 1 · 2024: 6 · 2023: 3 · 2022: 9 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 9 · 2015: 12 · 2014: 10 · 2013: 11 · 2012: 12
FWCI
3.04
Type
journal article
Language
en
Open access
closed
Locations
  • Trends in Pharmacological Sciences (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Israel Science Foundation
  • Ministry of Health, State of Israel
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
PARP1, ERK signaling, ERK2 phosphorylation, poly(ADP-ribosyl)ation, histone acetylation, Fos expression, epigenetic regulation, cell proliferation and differentiation
MeSH terms
Poly (ADP-Ribose) Polymerase-1, Animals, Enzyme Activation, Humans, Models, Biological, Poly(ADP-ribose) Polymerases, Signal Transduction, Protein Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review